GVHD, ACUTE
Clinical trials for GVHD, ACUTE explained in plain language.
Never miss a new study
Get alerted when new GVHD, ACUTE trials appear
Sign up with your email to follow new studies for GVHD, ACUTE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis phase 2 trial is testing whether adding the drug ruxolitinib to standard steroid treatment can better control severe acute graft-versus-host disease (GVHD), a serious complication after stem cell transplants. The study will enroll 54 people who develop severe GVHD within 100…
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for stem cell transplant patients: combo therapy targets severe GVHD
Disease control Recruiting nowThis study tests whether adding ruxolitinib to standard steroids works better than steroids alone for grade II acute graft-versus-host disease (GVHD), a common complication after stem cell transplant. About 168 adults who have had a first stem cell transplant for blood cancer and…
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug cocktail aims to stop deadly transplant complication
Disease control Recruiting nowThis phase 2 trial tests whether a new way of giving anti-thymocyte globulin (ATG) along with standard drugs tacrolimus and methotrexate can prevent acute graft-versus-host disease (GVHD) after a stem cell transplant. The study enrolls 29 adults aged 18-60 with blood cancers who …
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Simple blood test may predict deadly transplant complication
Knowledge-focused Recruiting nowThis study is testing whether two blood markers, CXCL9 and EASIX, can predict severe acute graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will take blood samples from 100 adult patients 28 days after transplant to see if these markers can spot early si…
Matched conditions: GVHD, ACUTE
Sponsor: Henry Ford Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC